PUBLIC COMPANY
saveParabilis Medicines
updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Windward nets $175M IPO, bringing 2026 biotech debuts to 35Windward Bio’s public debut brings this year’s IPO count well above the sluggish total of eight in 2025.biospace · 6d ago
- Once undruggable, the Wnt/B-catenin pathway shows increasing promiseEarly-stage clinical data from our company and others point to the Wnt/β-catenin pathway as a new avenue for targeting multiple cancer types.biospace · 20d ago
- Biotech IPOs raise $7.5B as sector’s performance rally flattensWhile biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same period was muted, with most of the yearly gains for the U.S. biotech-sp…biospace · 24d ago
- Protein degrader specialist Lycia prices $318M IPOFunds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.biopharma_dive · 27d ago
- Biotech notches 31 IPOs already this year, with 4 more joining queueThe sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts…biospace · 28d ago
- City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipelineCity Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.biospace · 1mo ago
- Iambic goes public with $150M IPO to accelerate clinical development of oncology pipelineIambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development of its oncology pipeline.fiercebiotech · 1mo ago
- The 2026 Biotech GraveyardFierce’s biotech graveyard is an annual tradition in which we remember all the companies we lost over the past year. While we're embracing the spooky spirit of Halloween, we hope the sad stories of…fiercebiotech · 1mo ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.fiercebiotech · 1mo ago
- Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listingEli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals brought in $116.7 million and $45 million from their respective IPOs, continuing a bumper year for biotech listings.fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that